$20.82
3.07%
Nasdaq, Jan 02, 10:02 pm CET
ISIN
US45257U1088
Symbol
IMNM

Immunome Inc Stock price

$20.82
+3.73 21.83% 1M
+12.19 141.25% 6M
-0.66 3.07% YTD
+10.29 97.72% 1Y
+18.61 842.08% 3Y
+11.07 113.54% 5Y
+7.37 54.80% 10Y
+7.37 54.80% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.66 3.07%
ISIN
US45257U1088
Symbol
IMNM
Industry

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$2.0b
Net debt
positive
Cash
$272.6m
Shares outstanding
91.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
237.3 | 311.5
EV/Sales
209.2 | 274.5
EV/FCF
negative
P/B
8.7
Financial Health
Equity Ratio
75.4%
Return on Equity
-161.7%
ROCE
-77.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$9.7m | $7.4m
EBITDA
$-205.0m | $-214.2m
EBIT
$-206.9m | $-213.8m
Net Income
$-222.7m | $-212.9m
Free Cash Flow
$-198.3m
Growth (TTM | estimate)
Revenue
-4.4% | -18.4%
EBITDA
-86.2% | -41.0%
EBIT
-85.2% | -39.3%
Net Income
27.1% | 27.3%
Free Cash Flow
-43.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,117.5% | -2,904.5%
EBIT
-2,137.1%
Net
-2,301.3% | -2,887.2%
Free Cash Flow
-2,049.1%
More
EPS
$-2.5
FCF per Share
$-2.2
Short interest
18.0%
Employees
155
Rev per Employee
$60.0k
Show more

Is Immunome Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Immunome Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Immunome Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Immunome Inc forecast:

Buy
94%
Hold
6%

Financial data from Immunome Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
9.68 9.68
4% 4%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 42 42
37% 37%
435%
- Research and Development Expense 174 174
91% 91%
1,802%
-205 -205
86% 86%
-2,117%
- Depreciation and Amortization 1.90 1.90
15% 15%
20%
EBIT (Operating Income) EBIT -207 -207
85% 85%
-2,137%
Net Profit -223 -223
27% 27%
-2,301%

In millions USD.

Don't miss a Thing! We will send you all news about Immunome Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunome Inc Stock News

Positive
Seeking Alpha
17 days ago
Immunome (IMNM) delivered statistically significant phase 3 RINGSIDE results for varegacestat in progressive desmoid tumors, achieving an 84% risk reduction in progression or death compared to placebo. Varegacestat demonstrated a 56% objective response rate, the highest ever in a randomized desmoid tumor trial, and a marked reduction in tumor volume. I maintain a "Strong Buy" rating, supported ...
Neutral
Business Wire
18 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. All of the shares are to be sold by Immunome. The gross proceeds...
Positive
The Motley Fool
19 days ago
A phase 3 study of varegacestat met its primary endpoint. The drug candidate could reduce the risk of disease progression or death in people with desmoid tumors by 84%.
More Immunome Inc News

Company Profile

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Head office United States
CEO Clay Siegall
Employees 155
Founded 2006
Website immunome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today